Pancreatic cancer is a resilient killer whose survival rates have hardly improved in recent decades. It is expected to become the second biggest cause of cancer-related death globally by 2030.

Pancreatic cancer is one of the deadliest types in the U.S., with a five-year survival rate of just 13%. One of the biggest challenges with the disease is that it’s often detected at a late ...

The research team found that not only was RAS(ON) multi-selective inhibition effective in preclinical pancreatic cancer models, but it was even more effective when combined with immunotherapy ...

He developed pancreatic cancer in 2020, when he was in his late 40s. 08:40 The tumor was already 4.5 centimeters in size, and had become intertwined with blood vessels, making it inoperable.

Despite progress in treatments for various cancers, pancreatic cancer continues to pose a significant challenge, with the NHS admitting that it "can be difficult to treat". Early detection is ...

Patients with pancreatic cancer have an overall poor prognosis: in most patients, the disease has already spread at the time of diagnosis, resulting in limited treatment options. Nearly 90 percent ...

WEST LAFAYETTE, Ind. — Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging diseases, starting with pancreatic ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...

In reality, Andraka created his potentially revolutionary pancreatic cancer detection tool at nearby Johns Hopkins University, though he does sometimes tinker in a small basement lab at the family ...